Biomarker ID | 1378 |
PMID | 24708576 |
Year | 2014 |
Biomarker | SMAD4 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 1.76 (95% CI: 1.15-2.71); Multivariate: HR: [1.73 (95% CI: 1.11-2.70)] |
Effect on Pathways | Pathways include: Cell cycle: G1/S checkpoint, NF-kappaB activation by non-typeable Hemophilus influenzae, TGF-beta receptor activation of SMADs, Heart development, CTCF pathway |
Experiment | Biochemical Failure Vs No Biochemical Faliure |
Type of Biomarker | Prognostic |
Cohort | 160 patients with PCa were selected for the analysis |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | Univariate: p=0.01 Multivariate; p=0.016 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | Time to BF was calculated from date of prostatectomy to the date of known BF, defined as the date of a PSA value ≥0.2 ng/mL (taken at least 6 weeks after surgery) and confirmed by a second PSA value >0.2 ng/mL. Time to BF was censored at the last date of contact for subjects who did not experience BF. |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |